We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+13.7%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$220M
AUM Growth
+$40.1M
Cap. Flow
+$16.3M
Cap. Flow %
7.42%
Top 10 Hldgs %
70.24%
Holding
28
New
2
Increased
7
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$16.5M
2
AMGN icon
Amgen
AMGN
+$4.41M
3
AVNS
Avanos Medical
AVNS
+$1.7M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$1.69M
5
UTHR icon
United Therapeutics
UTHR
+$915K

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$4.99M
2
MDCO
Medicines Co
MDCO
+$3.56M
3
ASRT
Assertio
ASRT
+$800K
4
IPXL
Impax Laboratories, Inc.
IPXL
+$486K
5
PFE icon
Pfizer
PFE
+$419K

Sector Composition

Rank Sector Weight
1 Healthcare 67.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$22.6M 10.27%
130,801
+6,000
+5% +$915K
IPXL
2
DELISTED
Impax Laboratories, Inc.
IPXL
$19.3M 8.77%
410,944
-12,217
-3% -$486K
AMAG
3
DELISTED
AMAG Pharmaceuticals
AMAG
$18.6M 8.49%
341,091
-7,951
-2% -$379K
TEVA icon
4
Teva Pharmaceuticals
TEVA
$40.8B
$15.5M 7.04%
248,200
+29,000
+13% +$1.69M
AVNS
5
DELISTED
Avanos Medical
AVNS
$15M 6.82%
304,150
+36,700
+14% +$1.7M
SCMP
6
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$14.5M 6.62%
933,866
-24,182
-3% -$375K
ENTA icon
7
Enanta Pharmaceuticals
ENTA
$366M
$13M 5.91%
+424,016
New +$16.5M
CNMD icon
8
CONMED
CNMD
$1.39B
$12.7M 5.78%
251,274
-6,843
-3% -$335K
MRK icon
9
Merck
MRK
$322B
$12M 5.48%
219,351
+5,454
+3% +$309K
OFIX icon
10
Orthofix Medical
OFIX
$477M
$11.1M 5.06%
309,698
-2,772
-0.9% -$87.1K
HRC
11
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$9.23M 4.2%
188,327
-7,773
-4% -$370K
AMGN icon
12
Amgen
AMGN
$208B
$9.11M 4.15%
57,000
+28,000
+97% +$4.41M
SRGA
13
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.4M 3.83%
56,715
+1,666
+3% +$254K
ASRT
14
DELISTED
Assertio
ASRT
$7.7M 3.51%
5,726
-650
-10% -$800K
AGN
15
DELISTED
Allergan plc
AGN
$6.53M 2.98%
21,954
-1,062
-5% -$303K
IVC
16
DELISTED
Invacare Corporation
IVC
$6.5M 2.96%
334,762
– –
ABBV icon
17
AbbVie
ABBV
$443B
$4.1M 1.87%
70,000
-5,500
-7% -$332K
VXRT
18
DELISTED
Vaxart
VXRT
$3.12M 1.42%
123,332
+19,047
+18% +$525K
INVA icon
19
Innoviva
INVA
$1.55B
$2.53M 1.15%
161,188
-10,671
-6% -$161K
JNP
20
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$1.96M 0.89%
316,149
– –
STRR
21
DELISTED
Star Equity Holdings
STRR
$1.91M 0.87%
8,392
– –
FURX
22
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$1.42M 0.65%
145,544
– –
LLY icon
23
Eli Lilly
LLY
$1.02T
– –
-2,143
Closed -$148K
PFE icon
24
Pfizer
PFE
$143B
– –
-14,173
Closed -$419K
MNK
25
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-50,395
Closed -$4.99M
1
2

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Krensavage Asset Management held 28 positions worth $220M, up 22% from $179M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Krensavage Asset Management deployed $16.3M of net new capital in Q1 2015, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Enanta Pharmaceuticals: 424,016 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier.

On the sell side, the largest reduction was Assertio, an estimated $800K trimmed.

  • Krensavage Asset Management's largest Q1 2015 buy was Enanta Pharmaceuticals: 424,016 shares worth $13M.
  • Krensavage Asset Management added most to Amgen in Q1 2015, an estimated $4.41M increase.
  • Krensavage Asset Management's biggest Q1 2015 reduction was Assertio, cutting an estimated $800K.
  • Krensavage Asset Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2015, selling an estimated $4.99M.
  • Krensavage Asset Management's ten largest holdings make up 70% of its $220M portfolio in Q1 2015.
  • Krensavage Asset Management opened 2 new positions and closed 5 in Q1 2015.
  • Krensavage Asset Management's portfolio value rose 22% quarter-over-quarter to $220M.

Based on Krensavage Asset Management's 13F filing for Q1 2015, filed 13 May 2015.